However, the multiplicity of actions of NF-κB could have the drawback that this type of therapy might entail disadvantageous effects: a reduction of the NF-κB activation could lead to an impairment of either the migration of natural killer (NK) cells or the concentration of the tumor infiltrating lymphocytes (TILS) and dendritic cells into the developing tumor. The gene discussed is NFKB1; the disease is neoplasm.